The U.S. Food and Drug Administration has approved the combination of imlunestrant (Inluriyo) with abemaciclib for the treatment of adults diagnosed with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer. This approval is specifically for patients who have experienced disease progression following endocrine therapy.

The treatment regimen requires the detection of the ESR1 mutation by an FDA-authorized test to ensure appropriate patient selection. This targeted approach reflects advances in personalized medicine for breast cancer, aiming to improve outcomes for this specific subgroup of patients.

Healthcare providers are advised to consider this new therapy option in the context of individual patient cases, particularly those with confirmed ESR1 mutations and prior exposure to endocrine treatments. This approval marks a significant addition to the therapeutic landscape for breast cancer management.